Non-Hallucinogenic DMT? Psilera Bioscience Reports Progress on ‘Well-Tolerated’ Derivative
Further in vivo studies with PSIL-002 will evaluate its antidepressant, anxiolytic, and anti-addictive properties, specifically targeting alcohol consumption.
Day: December 9, 2021
End of content
End of content